Mirena (Levonorgestrel)

Levonorgestrel is released locally from the device into the uterine cavity. It suppresses ovulation, thickens cervical mucus to block sperm, and induces endometrial atrophy, creating an environment that prevents fertilisation and implantation.

Mirena contains 52 mg of levonorgestrel that releases approximately 20 µg per day. The prescriber determines placement and duration; the device is intended to remain in place for up to five years before replacement.

Mirena is classified as pregnancy category X and must not be used by women who are pregnant or intend to become pregnant. Women may breastfeed after insertion, but the device should be removed if pregnancy occurs.

Submit an enquiry on the Mirena product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

The primary alternative is the copper IUD (e.g., Paragard), which provides non‑hormonal contraception. Mirena offers hormonal benefits such as reduced menstrual bleeding and endometriosis pain relief, whereas copper IUDs may increase menstrual flow. Choice depends on patient preference, medical history and desired side‑effect profile.

Mirena should be stored at ambient temperature, below 25 °C, in its original sealed packaging. Protect the device from moisture, direct sunlight and extreme temperatures to maintain the integrity of the levonorgestrel reservoir.

Mirena is inserted by a trained healthcare professional into the uterine cavity through the cervical canal using a specialized inserter. The procedure is performed in a clinical setting under aseptic conditions, and the device remains in place for up to five years.

Serious risks include uterine perforation during insertion or removal, pelvic inflammatory disease or severe infection, ovarian cyst formation, and rare severe allergic reactions such as anaphylaxis. Prompt medical attention is required if any of these events occur.

Mirena is contraindicated in women who are pregnant, have active pelvic infection, known or suspected breast cancer, unexplained vaginal bleeding, uterine anomalies that impede placement, or a history of thrombosis related to hormonal therapy.